Tango Therapeutics reported phase I/II data for vopimetostat (TNG‑462), a next‑generation PRMT5 inhibitor engineered for MTAP‑deleted tumors, that the company said justify a planned pivotal study in second‑line MTAP‑deleted pancreatic ductal adenocarcinoma. The early clinical readouts showed objective responses and progression‑free survival improvements versus historical chemotherapy benchmarks. Tango simultaneously executed a $225 million financing to support the Phase 3 program and broader development plans. Investors and company leadership framed the results as sufficient to pursue registration-intent studies in a notoriously refractory indication, while analysts flagged competitive PRMT5 programs from larger oncology players as potential market pressures.